Oligonucleotide therapeutics in cancer.
Alterations in pre-mRNA splicing can have profound effects on gene expression and lead to cellular transformation. Oligonucleotide therapeutics are drugs that manipulate gene expression and improve the disease state. Antisense oligonucleotides hybridize with a target mRNA to downregulate gene expression via an RNase H-dependent mechanism. Additionally, RNase H-independent splice switching oligonucleotides (SSO) modulate alternative or aberrant splicing, to favor the therapeutically relevant splicing product. This chapter summarizes the progress made in the application of these oligonucleotide drugs in the treatment of cancer.
AVI Biopharma, 3450 Monte Villa Parkway, Bothell, WA 98021, USA.
Jing
J
Wan
John A
JA
Bauman
Maria Anna
MA
Graziewicz
Peter
P
Sazani
Ryszard
R
Kole
D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D012333:RNA, Messenger
D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger